Latest Headlines

  1. New Uses For Existing Drugs To Combat Antimicrobial Resistance 11/18/2024

    In his recent doctoral thesis, defended at the University of Helsinki, Matej Zore investigated two drugs, fingolimod and etrasimod - initially developed to treat autoimmune diseases - for their potential to fight drug-resistant bacterial infections.

  2. NVIDIA Opens BioNeMo To Scale Digital Biology For Global Biopharma And Scientific Industry 11/18/2024

    NVIDIA today announced that global pharmaceutical and techbio industry leaders, academic pioneers and AI researchers are adopting the open-source NVIDIA BioNeMo Framework to advance drug discovery and accelerate molecule design.

  3. Perspectum Awarded New FDA Grant To Evaluate Biomarker For Rare Disease Drug Development 11/14/2024

    Perspectum, a leader in medical imaging quantification techniques, today announced that it has been awarded a 2024 U.S. Food and Drug Administration Drug Development Tool (DDT) Research Grant to evaluate a novel biomarker aimed at addressing the unmet needs of patients with rare diseases.

  4. STEERLife And Callidus Research Laboratories Forge Strategic Partnership To Accelerate Innovative Drug Development 11/13/2024

    STEERLife, a pioneer in pharmaceutical development technologies, and Callidus Research Laboratories, a formulation development services company with a wealth of experience in comprehensive pharmaceutical drug development, have forged a strategic partnership to accelerate drug development for global markets.

  5. iMetabolic Biopharma Receives Second NIH Grant Award For Drug Discovery 11/12/2024

    iMetabolic Biopharma Corporation (iMBP) is proud to announce that it has been awarded its second Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH).

  6. Recursion Announces The Release Of OpenPhenom-S/16 In Google Cloud's Model Garden 11/12/2024

    Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today the release of OpenPhenom-S/16, a publicly available foundation model in Google Cloud’s Vertex AI Model Garden.

  7. Schrödinger Announces Multi-Target Collaboration And Expanded Software Licensing Agreement With Novartis 11/12/2024

    Schrödinger, Inc. today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s portfolio for further development.

  8. Formation Bio Collaborates With Sanofi And OpenAI To Introduce Muse, A First Of Its Kind AI Tool To Accelerate Patient Recruitment In Drug Development 11/12/2024

    Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and improve drug development by optimizing patient recruitment for clinical trials.

  9. Arcturus Therapeutics Receives Clearance From FDA To Begin H5N1 Pandemic Flu Vaccine Clinical Trial 11/11/2024

    Arcturus Therapeutics Holdings Inc. a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a “Study Can Proceed” notification for the Company’s Investigational New Drug (IND) application, ARCT-2304, a self-amplifying mRNA (sa-mRNA) vaccine candidate for active immunization to prevent pandemic influenza disease caused by H5N1 virus.

  10. SystImmune, Inc. Announces FDA Clearance Of IND Application For BL-M17D1 In Advanced Solid Tumors 11/8/2024

    SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC) with a novel linker and payload technology.